- InVivo's financial position is solid, with existing cash to fund operations for another 16 months and access to another 3-4 years worth through its ATM.
- The clinical data being generated by the company's pilot study has been outstanding. I believe the company is revolutionizing how surgeons will treat spinal cord injury.
- I have built a detailed financial model that yields a stock price nearly double what the shares are trading for today.
Please read the article on Seeking-Alpha: LINK